New combo targets tough endometrial cancer in small trial

NCT ID NCT06518564

Recruiting now Disease control Sponsor: Panagiotis Konstantinopoulos, MD, PhD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether combining avelumab (an immunotherapy) with M1774 (a targeted drug) can shrink tumors or delay cancer growth in 25 people with ARID1A-mutated endometrial cancer that has returned after prior immunotherapy. Participants receive both drugs intravenously and by mouth. The main goals are to see how many respond and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: avelumab and M1774 (tuvusertib)
What this could lead to: If successful, this combination could offer a new treatment option for people with a specific genetic type of endometrial cancer that has come back after immunotherapy.
What could go wrong: This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The combination may cause side effects or fail to control the cancer long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARID1A GENE MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARID1A GENE MUTATION ENDOMETRIAL CANCER RECURRENT ENDOMETRIAL CARCINOMA

Contacts and locations

Locations

Brigham and Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.